Medical devices, healthcare technology and the business of care
510(k) clearance · K260508

LOBO Vascular Occlusion System

Okami Medical, Inc. · Decision date Apr 10, 2026

FDA DECISIONK260508

What did the FDA decide?

FDA records K260508 as a 510(k) premarket notification, with a decision dated Apr 10, 2026. The decision code SESE records a finding of substantial equivalence. This is a 510(k) clearance.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Cardiovascular
Decision date
Apr 10, 2026

FDA source record

Regulatory record facts

Identifier
K260508
Regulatory pathway
510(k) premarket notification
Product code
KRD
Decision code
SESE
Decision date
Apr 10, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Device, Vascular, For Promoting Embolization.

Product code
KRD
FDA device class
2

FDA decision timeline

  1. K260508 received

    Application receipt date recorded by FDA.

  2. K260508 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

Other records with product code KRD

Product / regulatory recordCompanyPathwayDecision dateSource
Okami Medical, Inc.510(k) clearanceOct 6, 2026FDA
Suzhou Haowei Medical Technology Co., Ltd.510(k) clearanceJul 31, 2026FDA
BOSTON SCIENTIFIC CORPORATION510(k) clearanceJul 24, 2026FDA
Medtronic, Inc.510(k) clearanceJun 24, 2026FDA
Nuvascular, Inc.510(k) clearanceJun 12, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Okami Medical, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Aliso Viejo, CA

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records